June 22 - 26, 2018
Boston Marriott Copley Place
Boston, Massachusetts, USA
Abstract submission deadline: Friday, April 6
Advance registration deadline: Friday, May 11
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
AACR has designated this live activity for a maximum of 27.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the CME Request for Credit Survey. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the AACR website and via email.Your CME certificate will be sent to you via email after the completion of the activity.
According to the latest data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program; Non-Hodgkin Lymphoma (NHL) is the seventh most common cancer in the United States with an estimated 72,240 new cases diagnosed in 2017. More than 20,000 individuals will die from NHL in 2017. Although lower in number than NHL, an estimated 8;260 new cases of Hodgkin Lymphoma (HL) will be diagnosed in 2017, with more than 1,000 deaths.
Dramatic increases in the five-year survival rates for both NHL and HL over the past fifty years have resulted in both NHL and HL being considered as success stories in terms of cancer survival. However, additional research and collaboration is needed in the early detection of these diseases and in the treatment and diagnosis of the lymphoma to reduce the number of new cases which has remained relatively flat.
The research being presented at this conference will address the need for more effective and earlier detection strategies, provide insights into new clinical decision-making tools, and discuss opportunities for innovative clinical trial designs and targeted therapeutic approaches across several subtypes of lymphoma. The program was designed to take advances in basic research areas and discuss how those are being applied, or have the potential to be applied for the betterment of patients in the clinic. Physician-scientists and clinicians will leave this program with new knowledge in the fields of gene editing, liquid biopsies, precision medicine trial design, early disease detection, and immunotherapy.
After participating in this CME activity, physicians should be able to:
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
This activity is supported by grants and will be disclosed at the activity.
Please contact the Office of CME at (215) 440-9300 or email@example.com.